Is UPenn profiting from COVID-19 vaccine approvals and sales? Read the BioNTech contract.

A university press release confirms that UPenn and its researchers ‘have received and may continue to receive significant financial benefits’ as the result of a 2018 contract with BioNTech.
Read more

Exit mobile version
Skip to toolbar